HIV Indicator Diseases Survey Across Europe

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Total Enrollment

2000 participants

Study Classification

OBSERVATIONAL

Study Start Date

2010-07-31

Study Completion Date

2014-02-28

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

In Europe many patients infected with HIV remain undiagnosed, although this percentage varies between 15-80% across the continent. In the UK it is estimated to be 27%. Undiagnosed HIV results in increased morbidity and mortality and reduced treatment response, as appropriate health interventions are delayed. It also has adverse public health implications, with those individuals unaware of their HIV status being more likely to transmit the virus.

An important public health issue is how to diagnose more individuals with HIV earlier in the course of their infection. In the US, the Centre for Disease Control and Prevention (CDC) has introduced testing guidelines whereby all individuals are tested, unless they object, at any point of contact with the healthcare system - the "opt-out" testing guidelines.

At the "HIV in Europe" Conference held in November 2007, the consensus, which included patient and public involvement, was that such an approach would not be suitable for Europe. The Conference recommended further development of focused HIV testing in patients presenting with certain clinical conditions and diseases - the "indicator disease'' testing guidelines.

Cost effectiveness analyses suggests cost savings if a screened population has an HIV prevalence of at least 1%, although this rate may be as low as 0.1%. However, there is very little - if any - evidence regarding HIV prevalence for certain conditions and diseases in specific and easy to identify sections of society. The focus of attention is on those conditions and diseases which occur more frequently in individuals known to be infected with HIV.

The aim of this study is to assess HIV prevalence for several diseases and conditions, within a specific segment of the population not yet diagnosed with HIV, who present for care with that specific disease or condition. These conditions have been selected as they occur frequently in individuals already diagnosed with HIV infection. This is a pilot study to inform phase two, which will involve more diseases and conditions with a wider participation of centres across Europe.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

HIV Indicator Diseases in Hospital and Primary Care

NCT05225493

HIV Infections Primary Health Care Acquired Immunodeficiency Syndrome +15 more

UNKNOWN

HIV Indicator Diseases Across Europe Study

NCT01681706

HIV

UNKNOWN

Factors Associated With Late HIV Diagnosis in Grampian: an Epidemiological Study

NCT02804724

Human Immunodeficiency Virus

COMPLETED

Understanding HIV Susceptibility in the Female Genital Tract

NCT03064425

HIV Infections

COMPLETED

2000 HIV Human Functional Genomics Partnership Program

NCT03994835

HIV Infections

COMPLETED

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

HIV AIDS Indicator Diseases/Indicator Conditions

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Study Time Perspective

CROSS_SECTIONAL

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Anal/cervical dyplasia

Any patient presenting for care with any degree of anal or cervical dysplasia

HIV test (serological or salivary)

Intervention Type OTHER

An HIV test will be offered to all patients accessing the healthcare setting for care of the "indicator" condition

Interview

Intervention Type OTHER

Demographic data will be collected for each patient consenting to an HIV test. With informed written consent, additional data will be collected from patients via focussed interview. Data comprises: previous medical history, previous health seeking behaviours, previous HIV testing history, previous viral hepatitis testing/diagnosis history, and assessment of HIV acquisition risk factors

STI

Any patient presenting for care with any non-HIV sexually transmitted infection

HIV test (serological or salivary)

Intervention Type OTHER

An HIV test will be offered to all patients accessing the healthcare setting for care of the "indicator" condition

Interview

Intervention Type OTHER

Demographic data will be collected for each patient consenting to an HIV test. With informed written consent, additional data will be collected from patients via focussed interview. Data comprises: previous medical history, previous health seeking behaviours, previous HIV testing history, previous viral hepatitis testing/diagnosis history, and assessment of HIV acquisition risk factors

Lymphoma

Any patient presenting for care with malignant lymphoma of any histological type

HIV test (serological or salivary)

Intervention Type OTHER

An HIV test will be offered to all patients accessing the healthcare setting for care of the "indicator" condition

Interview

Intervention Type OTHER

Demographic data will be collected for each patient consenting to an HIV test. With informed written consent, additional data will be collected from patients via focussed interview. Data comprises: previous medical history, previous health seeking behaviours, previous HIV testing history, previous viral hepatitis testing/diagnosis history, and assessment of HIV acquisition risk factors

Seborrhoeic dermatitis/exanthema

Any patient presenting for care with seborrhoeic dermatitis/exanthema

HIV test (serological or salivary)

Intervention Type OTHER

An HIV test will be offered to all patients accessing the healthcare setting for care of the "indicator" condition

Interview

Intervention Type OTHER

Demographic data will be collected for each patient consenting to an HIV test. With informed written consent, additional data will be collected from patients via focussed interview. Data comprises: previous medical history, previous health seeking behaviours, previous HIV testing history, previous viral hepatitis testing/diagnosis history, and assessment of HIV acquisition risk factors

Thromobocytopaenia/Leucopaenia, or hypergammaglobulinaemia

Any patient presenting for care with unexplained thromobocytopaenia/leucopaenia of more than four weeks duration, or with hypergammaglobulinaemia

HIV test (serological or salivary)

Intervention Type OTHER

An HIV test will be offered to all patients accessing the healthcare setting for care of the "indicator" condition

Interview

Intervention Type OTHER

Demographic data will be collected for each patient consenting to an HIV test. With informed written consent, additional data will be collected from patients via focussed interview. Data comprises: previous medical history, previous health seeking behaviours, previous HIV testing history, previous viral hepatitis testing/diagnosis history, and assessment of HIV acquisition risk factors

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

HIV test (serological or salivary)

An HIV test will be offered to all patients accessing the healthcare setting for care of the "indicator" condition

Intervention Type OTHER

Interview

Demographic data will be collected for each patient consenting to an HIV test. With informed written consent, additional data will be collected from patients via focussed interview. Data comprises: previous medical history, previous health seeking behaviours, previous HIV testing history, previous viral hepatitis testing/diagnosis history, and assessment of HIV acquisition risk factors

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Aged 16 years and over
* Presenting for care with one of the indicator diseases or conditions:

* A sexually transmitted disease
* Malignant lymphoma
* Cervical or anal dysplasia or cancer
* Unexplained leukocytopenia or thrombocytopenia lasting at least 4 weeks, or hypergammaglobulinaemia
* Seborrheic dermatitis or exanthema
* sub-study - consents to providing additional information